Table 1.
Baseline characteristics of 124 HIV/TB co-infected patients with CYP2B6-G516T genotypes in efavirenz and nevirapine groups.
| Baseline characteristics | Efavirenz group (n = 65) | Nevirapine group (n = 59) | ||||||
|---|---|---|---|---|---|---|---|---|
| CYP2B6-G516T | CYP2B6-G516T | |||||||
| GG | GT | TT | p-value | GG | GT | TT | p-value | |
| n = 25 | n = 31 | n = 9 | n = 26 | n = 31 | n = 2 | |||
| Sex Male: Female | 16: 9 | 21: 10 | 5: 4 | 0.795 | 17: 9 | 22: 9 | 1: 1 | 0.707 |
| Age years, mean (SD) |
36.48 (8.08) |
35.68 (8.82) |
35 (6.63) |
0.882 | 36.48 (8.08) |
35.68 (8.82) |
35 (6.63) |
0.467 |
| Body weight kg, mean (SD) |
52.9 (1.87) |
53.94 (1.89) |
52.22 (3.04) |
0.872 | 54.62 (2.06) |
54.7 (1.52) |
46.5 (6.5) |
0.489 |
| Alkaline phosphatase, U/L, mean (SD) |
149.2 (18.38) |
137.1 (16.91) |
233.9 (68.45) |
0.085 | 150.25 (28.9) |
113.97 (11.1) |
125 (4) |
0.458 |
| Aspartate aminotransferase U/L, mean (SD) | 32.8 (2.35) |
40.48 (3.32) |
43.22 (10.21) |
0.202 | 48.54 (7.31) |
35.58 (2.99) |
26 (1) |
0.167 |
| Alanine aminotransferase, U/L, mean (SD) | 27.0 (3.05) |
28.55 (2.89) |
31.22 (8.89) |
0.821 | 29.81 (3.95) |
27.94 (3.57) |
23.5 (5.5) |
0.877 |
| Total bilirubin, mg/dL, mean (SD) |
4.9 (4.34) |
0.56 (0.55) |
0.43 (0.07) |
0.452 | 2.97 (2.4) |
1.13 (0.57) |
0.6 (0.1) |
0.703 |
| Direct bilirubin, mg/dL, mean (SD) |
0.45 (0.14) |
0.37 (0.12) |
0.21 (0.05) |
0.631 | 0.28 (0.047) |
0.52 (0.199) |
0.30 (0.1) |
0.568 |
| CD4 count, cells/μl, median (IQR) |
41 (18-102) |
54 (24-120) |
67 (12.5-168) |
0.818 | 35.5 (23.5-97) |
45 (25-113) |
30.5 (23) |
0.595 |
| Log Plasma HIV-1 viral load median (IQR) |
5.90 (5.57-6.0) |
5.93 (5.39-6.0) |
5.64 (5.50-6.0) |
0.729 | 5.86 (5.46-6.0) |
5.60 (5.41-5.81) |
5.80 (Q1 = 5.59) |
0.041* |
* Statistically significant by Kruskal-Wallis test. SD: standard deviation. IQR: interquartile range.